TY - JOUR ID - 31699 TI - Development of Preventive Vaccines for Hepatitis C Virus E1/E2 Protein JO - Iranian Journal of Pathology JA - IJP LA - en SN - 1735-5303 AU - Ghasemi, Faezeh AU - Ghayour Mobarhan, Majid AU - Gouklani, Hamed AU - Meshkat, Zahra AD - Dept. of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran AD - Biochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran AD - Molecular Medicine Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran AD - Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Y1 - 2018 PY - 2018 VL - 13 IS - 2 SP - 113 EP - 124 KW - Hepatitis C Virus, E1 Protein, E2 Protein KW - Vaccine, Preventive Vaccines DO - 10.30699/ijp.13.2.113 N2 - Hepatitis C virus (HCV) is responsible for a vast majority of liver failure cases. HCV is a kind of blood disease appraised to chronically infect 3% of the worlds’ population causing significant morbidity and mortality. Therefore, a complete knowledge of humoral responses against HCV, resulting antibodies, and virus-receptor and virus-antibody interactions, are essential to design a vaccine. HCV epitopes or full sequence of HCV proteins can induce HCV specific immune responses. In fact, structural proteins are usually the main target of humoral responses and non-structural proteins are usually the main target of cellular responses. Hence, various vaccines based on distinct antigenic combinations are developed to prevent HCV infection and the current study tried to summarize them. UR - https://ijp.iranpath.org/article_31699.html L1 - https://ijp.iranpath.org/article_31699_096443bf2ebc6b370313ea636639bafc.pdf ER -